Overview
The objective of the TREAT TR study is to confirm the safety and performance of the TriClip System for tricuspid TEER in a contemporary, real-world setting, using the commercially available device in accordance with its approved indications for use.
Description
TREAT TR is a prospective, observational, single-arm, multi-center, post-market study designed to confirm the safety and performance of the TriClip System in a contemporary, real-world setting in accordance with its approved indications for use. The study will be conducted at up to 100 centers globally. Clinical investigation assessments will be conducted prior to the procedure to assess eligibility. Follow-up visits after the TriClip procedure will occur at discharge, 30 days, 6 months (telephone), 12 months, and annually through 5-years. An independent echocardiographic core laboratory (ECL) will be utilized for evaluating echocardiograms. An imaging substudy will be conducted at a subset of participating sites in up to 250 subjects who consent to participate in the substudy. Cardiac-gated computed tomography (CT) will be performed at baseline and 12 months to evaluate reverse cardiac remodeling.
Eligibility
Inclusion Criteria:
- Subject is eligible to receive the TriClip System per the current approved indications for use and is intended to undergo the procedure.
- Subject, or their legally authorized representative, has provided written informed consent prior to study procedure.
- Subject agrees to attend follow-up assessments.
- Subject is ≥ 18 years of age (or legal age of consent) at time of consent.
Exclusion Criteria:
- Subject is participating in another clinical study that could impact the follow-up or results of this study.
- Subject has an existing TriClip implant
- Presence of other conditions or factors that, in the Investigator's opinion, could limit the subject's ability to participate in follow-up.
